respiratory therapy News
-
Leading The Way in Neonatal Therapies
Buffalo Business First speaks to ONY Biotech about the company’s continued strides toward creating innovative therapies to improve outcomes for premature babies and their families. With a clinical trial for an aerosolized surfactant therapy recently completed and other product developments underway, ONY Biotech is poised to change the landscape of neonatal respiratory therapy as it’s ...
By ONY Biotech
-
MEKICS, Supplying 883 Ventilators to Chile Hospitals.
MEKICS, a company specializing in respiratory therapy, announced on the 13th that it has supplied a Ventilator 400 units to Chile Hospital. Starting with the supply of 270 ventilators through ©HEMISUR on March 29, 100 units on March 31, 100 units on April 1, 310 units on April 7, and 103 units on April 13. Thus, a total of 883 MEKICS ventilators will be located in the Chilean Ministry of ...
-
Vitalograph celebrates 60th anniversary
Founded in 1963, in Maids Moreton, Vitalograph’s mission has remained unwavering over the past six decades – to improve the lives of people living with lung conditions through the development and manufacture of respiratory diagnostic solutions. As experts in pulmonary function, they also provide clinical drug trial services that enable the development of life-changing respiratory ...
-
Yaguo Made the Second Donation
Yaguo Fight against the Epidemic!! Once again Yaguo have made a donation in order to support the frontline of the epidemic, helping with their innovating products that brings out intensive care and rehabilitation. On March 7th, YAGUO sent to Hubei a new set of respiratory devices, the number goes up to 100 devices worth around 2.2 million RMB, including bionic cough simulator (sputum removal ...
-
AG Industries Increases Production of Ventilator Filters More Than Fifteen Times its Pre-COVID Level, Prepares for Further Growth
AG Industries, which manufactures respiratory filters used in Ventilators, Oxygen Concentrators, and CPAP / BiPAP machines, has executed a 1,500% increase in production of its bacterial / viral filters used for the treatment of COVID-19 patients. With the demand for respiratory therapies continuing to surge due to COVID-19, AG Industries is positioned to continue its role as a critical supplier ...
-
NDD Medical Technologies reinforces commitment to respiratory therapy professionals with new spirometry training webinars
NDD Medical Technologies (NDD) is the leading provider of pulmonary function equipment, dedicated to the early detection and accurate diagnosis of COPD and other chronic lung diseases. In line with its continued commitment to supporting respiratory professionals—particularly in the wake of the COVID-19 pandemic—NDD is now offering free, live spirometry training sessions to provide ...
-
Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO
ALBUQUERQUE, N.M. (PRWEB) August 23, 2022 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug ...
-
Fighting COVID-19 ! We are together
Fighting the epidemic together – Yaguo and the Shanghai Tianyi Group donated 8-million-yuan worth of innovative respiratory equipment to help Hubei’s new coronavirus pneumonia epidemic. On February 18th 2020, Beijing Yaguo Technology Co., Ltd. (“Yaguo”) and the Shanghai Tianyi Industry Holding Group Co., Ltd. (“Tianyi”) jointly donated medical equipment with a ...
-
Hunterdon Healthcare Patients Benefit From Veinviewer To Reduce Sticks And PICCs
Hunterdon Medical Center, a 178-bed non-profit community hospital, and Christie Medical Holdings, Inc., a global leader in portable vein finders, today announced that use of the Christie VeinViewer® Vision2 is helping to improve the level of care provided to their patients. “A key goal for implementation of VeinViewer systems was to decrease the number of central lines placed in favor ...
-
Strong Demand for Lung Intelligence Accelerates VIDA`s Growth
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Since launching this latest addition ...
-
Om Pharma and Astrazeneca enter into Strategic Collaboration to Expand Presence in Respiratory and Immunology Fields in China
OM Pharma enters into a strategic collaboration agreement granting AstraZeneca the exclusive right to import and distribute the immunological therapy Broncho-Vaxom® for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan). OM Pharma and AstraZeneca celebrated their strategic collaboration agreement today at a partnership signing ...
-
Vitalograph expands Clinical Trial services portfolio with centralized DLCO, decentralized spirometry, and integrated oscillometry solutions.
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
-
BioIntelliSense Launches Patented, FDA-cleared Pulse Oximetry (SpO2) Sensor Technology that Addresses Skin Pigmentation and Motion Monitoring Challenges
Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices BioIntelliSense, a continuous health monitoring and clinical intelligence company, ...
-
Infection Prevention through Clean Water: How Healthcare Facilities Can Mitigate Healthcare-Associated Infections from Water
Healthcare-associated infections or HAIs are infections people get while they are receiving health care for another condition. These infections can happen in all types of healthcare settings and are a significant cause of patient illness and death. According to the Centers for Disease Control and Prevention (CDC), 1 in 31 patients experience a healthcare-associated infection on any given day, ...
-
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective November 15, 2021. “Barry is a seasoned financial executive who brings decades of experience in business development and corporate finance having ...
-
Nob Hill Therapeutics Selected as a Finalist for RESI Innovator’s Pitch Challenge
Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. The IPC focuses on early-stage life science companies actively raising capital and ...
-
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases today announces the signing of an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. (“Chance”) to develop and commercialize Aerami’s drug ...
-
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing Plans to enter Phase 2/3 Trials in early 2022 Aerami Therapeutics, Inc. a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and ...
-
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
By AlloVir
-
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System
Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off mechanical ventilation and breathe on ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you